Modified growth hormone fragment 177-191

AOD-9604 in Canada

Also known as AOD9604 · Anti-obesity drug 9604 · Tyr-hGH 177-191 · Modified growth hormone fragment 177-191 · HGH Fragment 176-191

AOD-9604 is a synthetic 16-amino-acid peptide built from the C-terminal region of human growth hormone, with a tyrosine at the N-terminus for stability. Developed by Metabolic Pharmaceuticals in Australia as an oral anti-obesity drug, it reduced fat mass in rodents without growth hormone's effects on glucose or IGF-1, then went through Phase 2 trials in nearly a thousand people where it proved safe but did not meet its weight-loss endpoint. Canada Peptides carries research-grade AOD-9604 as a lyophilised vial, priced and shipped in CAD for laboratory and research use only.

Quick facts

Class: Synthetic hexadecapeptide; modified C-terminal fragment of human growth hormone
Structure: 16 amino acids · Tyr-hGH(177-191) · Cys-Cys disulfide bridge · ~1,815 Da
Half-life: No published human pharmacokinetic study of the injectable form; oral exposure in trials was low; rodent clearance is rapid
Route in research: Oral tablets in all human trials; intraperitoneal, oral and subcutaneous in rodent studies; intra-articular in one rabbit study
Cadence in research: Once daily in the human trials and most animal protocols
Storage: Lyophilised: refrigerated, dark. Reconstituted: refrigerated, used within weeks
Status in Canada: No Health Canada market authorisation or DIN. Research use only

AOD-9604 FAQ

Is AOD-9604 for sale in Canada?

Yes. Research-grade AOD-9604 is available in Canada from Canada Peptides as a lyophilised vial, priced and shipped in CAD. It is supplied strictly for laboratory and research use, not for human consumption.

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide from the C-terminal region of human growth hormone, developed by Metabolic Pharmaceuticals in Australia as an oral anti-obesity drug. It was studied because that region carries growth hormone's effects on fat metabolism without its effects on growth or glucose.

Did AOD-9604 work in human trials?

Not on the primary endpoint. The Phase 2b trial in about three hundred obese adults did not show enough weight loss versus placebo over twelve weeks, and development was discontinued. The trials did show good tolerability and no effect on glucose or IGF-1.

Is AOD-9604 the same as HGH Fragment 176-191?

Yes, at the level of sequence. AOD-9604 is residues 177–191 of growth hormone with a tyrosine added at the N-terminus, and residue 176 of the hormone is itself a tyrosine, so both names describe the same sixteen residues. Both are sold here under the names researchers search for.

What is the half-life of AOD-9604?

Unknown for the injectable form. No human pharmacokinetic study of injected AOD-9604 has been published; the human trials used oral tablets with low systemic exposure, and rodent data show rapid clearance. Half-life figures circulated online are not derived from published data.

How was AOD-9604 dosed in studies?

Human trials used oral tablets from 1 mg to 30 mg once daily for up to twelve weeks. Rodent studies used roughly 0.25–2 mg/kg daily. There is no validated human dose for the injectable material, and this page does not recommend one; the material sold here is for research use only.

Is AOD-9604 GRAS or FDA approved?

Neither in the sense usually implied. A GRAS self-affirmation for low oral doses in foods was reported in 2014; that is a company-panel determination, not an FDA approval, and it does not cover injections. In 2023 the FDA separately declined to allow AOD-9604 in compounded medicines.

Is AOD-9604 legal in Canada?

AOD-9604 is not a controlled substance in Canada, but it has no Health Canada approval for human use and no DIN. It may be sold for laboratory research, which is how it is sold here. WADA names AOD-9604 under S2, so it is prohibited for tested athletes.

AOD-9604 in Canada

Quick facts

AOD-9604 — for sale in Canada

What is AOD-9604?

Evidence at a glance

Pharmacology

Identity and chemistry

Storage and stability

Research indications

Research protocols

Interactions and stacking in research

Reconstitution and handling

Side effects and safety signals

Regulatory status in Canada

Further reading

AOD-9604 FAQ

Research references